What Moolec Science does

Moolec Science SA is a molecular farming company that produces animal proteins and specialty oils in genetically engineered crops, trading on NASDAQ under ticker MLEC following a June 2025 business combination with Bioceres Group, Gentle Technologies, and Nutrecon. The company's core technology is a plant-based expression platform that inserts target genes into safflower and pea seeds, producing functional ingredients at agricultural scale. Its lead commercial platform, GLASO1, yields gamma-linolenic acid (GLA)-rich safflower oil at approximately 45% concentration at commercial scale across 1,100 acres in the U.S., with 2025 campaign yields up 57% year-over-year. In April 2026, the company announced the first successful stable expression of bovine myoglobin in pea seeds via a 28-month sponsored research project with a U.S. academic institution, expanding the platform beyond oil crops into structured protein production.

Moolec generates revenue through direct B2B enterprise sales of GLA-rich safflower oil and specialty ingredients, initially targeting pet food manufacturers with planned expansion into human nutrition, dietary supplements, and specialty ingredient markets, and is also pursuing renewable energy feedstock applications through safflower. Following the 2025 merger, the portfolio was broadened to include the Mycofood™ fungal precision fermentation platform (acquired June 2025) and HB4® drought-tolerant soybeans through a supply agreement with Bioceres Crop Solutions. Pricing is not publicly disclosed. The company sells direct to enterprise customers leveraging existing U.S. agricultural and processing infrastructure.

Moolec is controlled by Union Group (founded by Uruguayan businessman Juan Sartori), employs 11-50 staff, and is headquartered in Warwick, UK, with a legal domicile in Uruguay and operations spanning the United States, Argentina, Australia, and Europe. The company has raised approximately $80 million since 2023, including a $50 million committed equity facility from Nomura (April 2023) and a $30 million convertible note financing led by Grupo Insud with Bioceres Crop Solutions (October 2023). It holds USDA-APHIS approval for its GLASO1 ingredient and SENASA feed/food approval in Argentina for safflower GLASO technology. The company regained Nasdaq minimum stockholders' equity compliance in May 2026 after a non-compliance notice in late 2025, and its market capitalization stood at approximately $5.28M as of April 2026 following a ~95.67% stock decline over the prior year.

Name

Moolec Science

Legal name

Moolec Science SA

Website

https://moolecscience.com

Company type

Public

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Moolec Science is a molecular farming company producing GLA-rich safflower oil and animal proteins (e.g., bovine myoglobin) in genetically engineered plants, serving B2B customers in pet food, human nutrition, and dietary supplements. It trades on NASDAQ as MLEC after its June 2025 merger with Bioceres Group.

Ownership category

akta.pro rank

Product category

Alternative Protein Ingredients

NAICS

Fats and Oils Refining and Blending (311225), Dog and Cat Food Manufacturing (311111), Starch and Vegetable Fats and Oils Manufacturing (31122), Other Animal Food Manufacturing (311119)

SIC

Fats & Oils (2070)

akta.pro primary industry

Alternative Protein & Sustainable Pet Food (insect/plant/cell-based) (CRADAFAI)

akta.pro secondary industries

Specialty & Tropical Oils Processing (Avocado, Sesame, Peanut, Rice Bran, Grapeseed) (AFAKAEAE), Mycoprotein-Based Foods Manufacturing (AFAKAGAG), Bio-based Animal Feed Ingredients & Nutrition Co-products (e.g., DDGS, protein meals, yeast) (EUAAAIAI), Phytogenics & Botanicals (Essential Oils, Plant Extracts) (AFADAKAF)

Keywords

• Molecular farming proteins
• Alternative protein ingredients
• Specialty oil ingredients
• Plant-based proteins
• Precision fermentation ingredients

Headquarters

HQ city

Warwick

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. GLA-Rich Safflower Oil Sales: Revenue from commercial-scale production and sale of GLA-enriched safflower oil to pet food, human nutrition, and dietary supplement markets.
2. Specialty Ingredients: Revenue from high-concentration GLA softgel applications and specialty ingredient sales to nutrition and supplements market.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

Moolec Science develops and produces animal proteins and specialty oils using molecular farming technology—genetically engineering crops such as safflower and peas to express high-value proteins (e.g., bovine myoglobin) or fatty acids (e.g., gamma-linolenic acid/GLA). Its commercial flagship is the GLASO1 safflower platform producing GLA-rich safflower oil at commercial scale for pet food, human nutrition, and dietary supplement applications. The company also operates the Mycofood™ fungal precision fermentation platform acquired through its 2025 merger.

Product overview

Moolec Science is a molecular farming company that develops animal proteins in plants across the US, Europe, and South America. The company operates primarily through its GLASO1 Safflower Platform, which produces GLA-rich safflower oil at commercial scale, and its Molecular Farming Platform, which expresses proteins like bovine myoglobin in crops such as pea seeds. Following its 2025 business combination with Bioceres Group, Gentle Technologies, and Nutrecon, the company expanded to include the Mycofood™ fungal precision fermentation platform. The portfolio also includes HB4® soybeans through a supply agreement with Bioceres Crop Solutions. The company is transitioning from development to commercialization, with initial market traction in pet food and expansion planned into human nutrition and dietary supplements.

Differentiator

Problem solved

Functional benefit

Brands

• GLASO1: GLA-enriched safflower platform producing gamma-linolenic acid oil at commercial scale
• Mycofood™

Products and services

• GLASO1 Safflower Platform (GLA-Rich Safflower Oil) A plant-engineered molecular farming platform producing gamma-linolenic acid (GLA)-rich safflower oil at commercial scale. The platform achieves approximately 45% GLA concentration, with 52 elite genotypes exceeding 60% from 320 candidates. Sold to pet food, human nutrition, dietary supplement, and specialty ingredient manufacturers.
• Molecular Farming Platform (Bovine Myoglobin in Pea Seeds) A plant-based protein expression platform demonstrating stable, multi-generational expression of bovine myoglobin in pea seeds. Expands the company's molecular farming capabilities beyond safflower into alternative crops, targeting alternative protein production for food applications.
• Mycofood™ Fungal Precision Fermentation Platform A fungal precision fermentation platform for producing specialty food ingredients. Acquired through the June 2025 business combination and integrated as a wholly owned subsidiary, enabling alternative protein and specialty ingredient production via fermentation technology.
• HB4® Soybeans Drought-resistant soybean technology accessed through a supply agreement with Bioceres Crop Solutions, featuring proprietary HB4® gene technology for enhanced crop resilience. Available to support sustainable soybean supply for the company's research, development, and commercialization operations.

Quantifiable outcome

• 45% GLA concentration at commercial scale from 1,100 acres, 57% yield increase year-over-year
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor.

• Major Global Agribusiness CompanyminorStrategic or Co-development PartnerStrategic research collaboration with a major global agribusiness company for development of next-generation safflower platforms.
• U.S. Academic InstitutionminorStrategic or Co-development Partner28-month sponsored research project with a U.S. academic institution resulting in successful production of bovine myoglobin in pea seeds, demonstrating stable protein expression across multiple generations.
• Australia Germplasm SourcesminorStrategic or Co-development PartnerAccess to germplasm library of 386 safflower varieties sourced from Australia for renewable energy feedstock development and next-generation platform advancement.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cibus: Public gene-editing and trait-development company for oilseed crops; directly comparable as a small-cap public plant-biology platform targeting specialty oil and trait economics, and explicitly used as a peer in published Moolec comparisons.
• Benson Hill: Plant biology company using genomics and trait development to produce specialty plant-based ingredients for food and feed; comparable technology stack and go-to-market motion into CPG and pet food customers.
• Calyxt: Plant-based trait development company focused on specialty oil and ingredient profiles in commodity crops; closely aligned on the model of monetizing differentiated crop output via B2B ingredient sales.
• Pairwise: Gene-editing company developing novel crop traits for food and agriculture; comparable in plant-based trait platform targeting fruit, oilseed, and ingredient applications with B2B customer focus.
• Bioceres Crop Solutions: Argentine agtech company with HB4 drought-tolerant soy/wheat traits and an established agricultural inputs business; effectively Moolec's own operating subsidiary post-merger and a direct functional peer in agricultural biotechnology.

Emerging players

• BioBetter: Israeli molecular farming company producing complex proteins in tobacco plants for food and therapeutic applications; directly comparable technology approach of expressing high-value proteins in plant hosts.
• IngredientWerks: Molecular farming company producing functional proteins (including heme and other animal proteins) in plants; one of the closest technology analogues to Moolec's bovine myoglobin program.
• Bond Pet Foods: Precision fermentation company producing animal proteins (starting with chicken) for the pet food industry; directly comparable target end-market and B2B selling motion into pet food customers.

Broad incumbents

• Perfect Day: Precision fermentation leader producing animal-free dairy proteins at commercial scale; comparable as a B2B alternative-protein ingredient supplier targeting food and nutrition customers with a technology-led cost-down roadmap.
• Veramaris: DSM/Evonik joint venture producing omega-3 fatty acids (EPA/DHA) from algae for pet food and aquaculture feed; comparable as a specialty-ingredient supplier selling novel fatty acid profiles into pet food and nutrition end markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/moolec-science

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moolec Science